Tobacco company Philip Morris International (NYSE: PM) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 9.1% year on year to $10.15 billion. Its non-GAAP profit of $1.96 per share was 7.1% above analysts’ consensus estimates.

Is now the time to buy PM? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Philip Morris’ first quarter results were shaped by robust international demand for its smoke-free products and resilient pricing power across both smoke-free and traditional cigarettes. Management attributed the strong revenue growth to double-digit volume gains in IQOS and VEEV, as well as broad-based pricing increases. CEO Jacek Olczak noted that, “Our results continue to be underpinned by three powerful drivers: strong pricing, favorable mix from the ongoing shift to smoke-free products, and volume growth led by IQOS, ZYN, and VEEV.” Despite these gains, the U.S. segment faced challenges from inventory normalization and increased promotional activity, which weighed on profitability.

Looking forward, Philip Morris’ guidance is anchored by expectations for continued international momentum in smoke-free categories, the launch of new ZYN innovations in the U.S., and ongoing cost management. Management expects U.S. performance to improve as inventory disruptions subside and new products come to market, with Olczak emphasizing, “We are preparing our manufacturing and commercial operations for new product launches in the coming months.” The company remains focused on expanding its global smoke-free footprint and believes that high single-digit volume growth in these products will drive results, even as macroeconomic uncertainty and regulatory changes remain potential headwinds.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to strong international smoke-free growth, robust pricing, and effective cost management, while U.S. challenges stemmed from inventory normalization and increased investment in ZYN.

• International smoke-free acceleration: Double-digit growth in IQOS and VEEV underpinned performance, with broad-based momentum across Europe, Japan, and new markets like Taiwan, which saw rapid adoption following recent launches.
• Pricing power remains strong: Management highlighted that pricing contributed significantly to top-line growth, with combustible pricing up 8.5% and international smoke-free products benefiting from premium positioning and moderate price increases.
• U.S. segment normalization: ZYN shipment volumes in the U.S. were impacted by inventory corrections and increased promotional activity compared to minimal promotions last year. Management expects these factors to normalize, supporting improved performance in the second half of the year.
• Innovation pipeline advancing: The company continued to invest in product innovation, including the national rollout of Bonds by IQOS in Italy and the expansion of ZYN’s flavor and strength portfolio internationally, as well as preparations for new ZYN product launches in the U.S.
• Cost efficiency initiatives: Approximately $150 million in gross cost savings were realized during the quarter, helping offset increased investment in smoke-free marketing and commercial operations and supporting margin stability despite ongoing economic and regulatory pressures.

Drivers of Future Performance

Management sees international smoke-free growth, ZYN innovation in the U.S., and disciplined investment as the primary themes for the rest of the year.

• Smoke-free volume expansion: The company expects high single-digit volume growth in smoke-free products, led by IQOS, ZYN, and VEEV. Management believes international markets will continue to drive gains, especially as launches in new geographies gain traction and existing markets mature.
• U.S. recovery and innovation: After a transition period marked by inventory normalization and increased promotions, management anticipates sequential improvement in U.S. performance. The launch of new ZYN product formats is expected to recapture momentum in the nicotine pouch segment and address evolving consumer preferences.
• Regulatory and cost headwinds: The outlook factors in continued investment, possible excise tax changes in the U.S., and macroeconomic uncertainty, with management emphasizing ongoing cost optimization and supply chain productivity as key levers for maintaining profitability.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the pace of adoption for new ZYN innovations in the U.S. and their impact on shipment volumes, (2) continued momentum and market expansion of IQOS and VEEV in key international geographies, and (3) the company’s ability to sustain pricing power and margin stability amid regulatory changes and potential excise tax shifts. Execution on cost efficiency and innovation rollouts will also be critical signposts.

Philip Morris currently trades at $163.98, up from $153.25 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.